Posted by Michael Wonder on 29 May 2023
Lexicon announces FDA approval of Inpefa (sotagliflozin) for treatment of heart failure
26 May 2023 - Inpefa granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes.
Lexicon Pharmaceuticals today announced that the US FDA has approved Inpefa (sotagliflozin), a once daily oral tablet to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
